<DOC>
	<DOCNO>NCT02929498</DOCNO>
	<brief_summary>This Phase I/II , open-label , 2 arm study evaluate safety clinical activity GSK2879552 alone , combination azacitidine subject MDS . The study consist 2 part . The objective Part 1 determine recommend phase 2 dose ( RP2D ) GSK2879552 administer alone combination azacitidine adult subject high risk MDS previously treat HMA . The objective Part 2 evaluate clinical activity treatment GSK2879552 , alone combination azacitidine , adult subject high risk MDS previously treat HMA .</brief_summary>
	<brief_title>Safety , Clinical Activity , Pharmacokinetics ( PK ) Pharmacodynamics Study GSK2879552 , Alone With Azacitidine , Subjects With High Risk Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>&gt; =18 year age provide sign write informed consent Subjects must IPSSR high high risk myelodysplastic syndrome ( MDS ) World Health Organization ( WHO ) classification Subjects must fail hypomethylating treatment `` failure '' define : Progression ( accord 2006 International Working Group [ IWG ] criterion ) time initiation hypomethylating treatment OR Failure achieve complete partial response hematological improvement ( HI ) ( accord 2006 IWG ) least 4 cycle treatment OR Relapse initial complete partial response HI ( accord 2006 IWG criterion ) . Subjects candidate , fail allogeneic stem cell transplantation . Subjects underwent allotransplant past eligible follow condition : transplant &gt; 2 year prior enrolment , evidence active graftversushost disease ( GVHD ) Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Subjects must life expectancy least 12 week , opinion investigator . Able swallow retain orally administer medication clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel . All prior treatmentrelated toxicity must National Cancer Institute Common Toxicity Criteria Adverse Events ( NCICTCAE ) , version 4.0 &lt; =Grade 1 time enrollment ( except alopecia ) . Adequate baseline organ function define : International Normalization Ratio ( INR ) activate partial thromboplastin time ( aPTT ) &lt; =1.3xupper limit normal ( ULN ) ; platelet count ( PLT ) &gt; =10,000 ( transfusion permit bring PLT &gt; 10,000 ) ; total bilirubin &lt; =1.5xULN ( Isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % subject diagnosis Gilbert 's syndrome ) ; Alanine transaminase ( ALT ) &lt; =2.5xULN ; creatinine &lt; =1.5xULN OR calculate creatinine clearance Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) equation measure 24 hour urine &gt; =50 milliliter ( mL ) /minute ( min ) ; Ejection fraction &gt; =lower limit normal ( LLN ) Echocardiogram ( ECHO ) multigated acquisition scan ( MUGA ) Women childbearing potential must negative serum pregnancy test within 7 day first dose study treatment agree use effective contraception study 7 day follow last dose study treatment . Men female partner childbearing potential must either prior vasectomy agree use effective contraception administration first dose study treatment 3 month last dose study treatment allow clearance alter sperm . AML accord world health organization ( WHO ) criterion ( i.e . bone marrow blast &gt; 20 % ) Active hepatitis B hepatitis C treatment Baseline Montreal Cognitive Assessment ( MOCA ) score 22 low History concurrent malignancy solid tumour , except : Exception : Subjects diseasefree 2 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Prior treatment temozolomide , dacarbazine procarbazine Prior treatment poly adenosine diphosphate ( ADP ) ribose polymerase ( PARP ) inhibitor ( example ( e.g . ) , olaparib , veliparib [ ABT888 ] ) Currently receive anticancer therapy ( chemotherapy , radiation therapy , immuno therapy , biologic therapy , hormonal therapy , surgery , and/or tumour embolization ) Received major surgery , radiotherapy , immunotherapy within 4 week GSK2879552 administration Evidence severe uncontrolled systemic disease ( e.g. , severe/chronic infection , unstable uncompensated respiratory , renal , cardiac disease ) . Any serious and/or unstable preexist medical ( aside malignancy exception ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure , opinion Investigator Current active liver biliary disease ( exception Gilbert 's syndrome asymptomatic gallstone otherwise stable chronic liver disease per investigator 's assessment ) Patients major bleed current within past 4 week . ( e.g . recent gastrointestinal [ GI ] hemorrhage neurosurgery ) . Administration investigational drug within 14 day 5 halflives , whichever short , precede first dose study treatment ( ) study . Cardiac abnormality evidence follow : clinically significant uncontrolled arrhythmia uncontrolled hypertension ; history evidence current &gt; =Class II congestive heart failure define New York Heart Association ( NYHA ) ; history acute coronary syndrome ( include unstable angina myocardial infarction ) , coronary angioplasty , stenting within past 3 month ; baseline Corrected QT ( QTc ) interval use Fridericia 's formula &gt; 450 millisecond ( msec ) &gt; 480 msec subject Bundle Branch Block . QTc value base single average triplicate ECGs obtain brief recording period Current use prohibit medication include anticoagulant platelet inhibitor expect require medication treatment investigational drug Consumption Seville orange , grapefruit , grapefruit hybrid , grapefruit juice , pommelos , exotic citrus fruit , 1 day prior first dose study treatment ( ) last dose study drug Lactating female Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate GSK2879552 lysinespecific demethylase 1 ( LSD1 ) inhibitor contraindicate participation Known hypersensitivity azacitidine mannitol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>GSK2879552</keyword>
	<keyword>Revised International Prognostic Scoring System ( IPSS-R )</keyword>
	<keyword>azacitidine</keyword>
	<keyword>hypomethylating agent</keyword>
	<keyword>myelodysplastic syndrome</keyword>
</DOC>